#	Pagina
attuale pagina	/open-h2020/projects/219927/index.html
-1	/open-h2020/per-topic/compile/list/index.html
-2	/open-h2020/projects/209270/index.html
-3	/open-h2020/projects/193733/index.html
-4	/open-h2020/per-topic/hotflow/list/index.html
-5	/open-h2020/projects/203409/index.html
-6	/open-h2020/per-topic/2a/list/index.html
-7	/open-h2020/per-topic/1313/list/index.html
-8	/open-h2020/projects/215680/index.html
-9	/open-h2020/per-topic/borderlands/list/index.html
-10	/open-fp7/projects/90054/index.html

Opendata, web and dolomites

POLYMMUNE SIGNED

Off-the-Shelf Polypeptide-based Immunotherapy for Advanced Melanoma Treatment

Total Cost €

EC-Contrib. €

Partnership

Views

POLYMMUNE project word cloud

Explore the words cloud of the POLYMMUNE project. It provides you a very rough idea of what is the project "POLYMMUNE" about.

blood platform polymeric desired severe intranasally clinical outcome depending brain medicine conjugates 132 globally consolidator nanogel neck ing viability will causing medical polymmune envision cheaper therapeutics additionally diagnosed therapeutic melanoma grant action nanoconjugates costly invest shelf variety nanocarrier fold dual diseases patients companies pharmaceutical drug biotechnology erc vaccine immunotherapy site bypass types immune commercially proof barrier industrially activate despite commercial antigen minimising heavily strategies successes effects activated interplay treatments off treatment 50 scalable offers neurodegenerative benefit cancer conjugate coupling broad modification mynano drugs reactions immunotherapies potentially metastatic attractive business administered bottle overcome

Project "POLYMMUNE" data sheet

The following table provides information about the project.

Coordinator	FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE Organization address address: CALLE EDUARDO PRIMO YUFERA 3 city: VALENCIA postcode: 46012 website: http://www.cipf.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	149˙938 €
EC max contribution	149˙938 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2018-PoC
Funding Scheme	ERC-POC
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2020-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE Organization address address: CALLE EDUARDO PRIMO YUFERA 3 city: VALENCIA postcode: 46012 website: http://www.cipf.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALENCIA)	coordinator	149˙938.00

Map

Project objective

Despite various existing drug delivery methods, the key challenge remains: how to deliver drugs to the desired site of therapeutic action to achieve best treatment outcome, while minimising side effects? This is even more challenging in cancer immunotherapy as a complex interplay of immune reactions need to be activated. POLYMMUNE will evaluate the technical and commercial viability of our novel polymeric nanocarrier platform (developed during my ERC Consolidator grant MyNano) for targeted drug delivery of a wide variety of diseases and therapeutics. As proof of concept, we will focus on immunotherapy delivery for metastatic melanoma. Globally ~132,000 new melanoma cases will be diagnosed each year and despite recent successes, only 50% of the patients respond to novel immunotherapies that are costly, while causing severe side effects. Coupling a commercially available antigen against metastatic melanoma to our nanocarrier will activate a broad immune response, resulting in an effective cancer vaccine that potentially targets different melanoma types, enabling off-the-shelf production. This dual action will lead to increased clinical benefit, which will come with less side effects and will be 5-10-fold cheaper than current treatments. Additionally, our conjugate is industrially scalable and thus overcome a major bottle neck of current nanocarrier-based medicine. We envision our platform technology to be used as a method of choice for drug delivery in many medical applications, such as cancer immunotherapy and neurodegenerative diseases. These applications are within reach, as depending on the modification, our conjugates can e.g. bypass the blood brain barrier and potentially be administered intranasally (nanogel). Our platform offers a highly attractive business case, as biotechnology and pharmaceutical companies heavily invest in nanoconjugates due to the need for novel drug delivery strategies.

Publications

List of publications.
year	authors and title	journal	last update
2019	Liane I. F. Moura, Alessio Malfanti, Carina Peres, Ana I. Matos, Elise Guegain, Vanessa Sainz, Mire Zloh, MarÃa J. Vicent, Helena F. Florindo Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders published pages: , ISSN: 2051-6347, DOI: 10.1039/c9mh00628a	Materials Horizons Advanced article	2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYMMUNE" are provided by the European Opendata Portal: CORDIS opendata.